Update of tacrolimus in pancreas transplantation

Diabetic Medicine

Volumn 14, Issue 11, 1997, Pages 911-918

  Wijnen, R R ^a,b   Ericzon, B G ^c  

^a CATHARINA HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes mellitu; FK506; Immunosuppression; Pancreas transplantation; Tacrolimus

Indexed keywords

TACROLIMUS;

DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PANCREAS ISLET TRANSPLANTATION; REVIEW;

EID: 0030828828     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199711)14:11<911::AID-DIA513>3.0.CO;2-7     Document Type: Review

References (127)

1. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 584.
2. Morley AR. Renal vascular disease in diabetes mellitus. Histopathology 1988; 12: 343-358.
3. Groop LC, Teir H, Koskimies HT, Groop PH, Matikainen E, Verkkala E. Risk factors and markers associated with proliferative retinopathy in patients with insulin-dependent diabetes. Diabetes 1986; 35: 1397-1403.
4. Hoyd CE, Becher D, Ellis D, Orchard TJ. Incidence of complications in insulin-dependent diabetes mellitus: a survival analysis. Am J Epidemiol 1996; 143: 431-441.
5. Cerami A, Vlassara H, Brownlee M. Role of advanced glycosylation products in complications of diabetes. Diabetes Care 1988; 11 (suppl 1): 73-79.
6. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992; 15: 1835-1843.
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
8. The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment in quality of life outcomes in the diabetes control and complications trial. Diabetes Care 1996; 19: 195-203.
9. Godine JE. The relationship between metabolic control and vascular complications of diabetes mellitus. Med Clin North Am 1988; 72: 1271-1284.
10. Santiago JV. Clinical review 38: intensive management of insulin dependent diabetes: risks, benefits, and unanswered questions. J Clin Endocrinol Metab 1992; 75: 977-982.
11. Williams PW. Notes on diabetes treated with extract and graft of sheep's pancreas. Br Med J 1884; 2: 1303-1304.
12. Ottolenghi D. Sur la transplantation du pancréas. Arch Ital Biol 1901; 36: 447-454.
13. Tiberti N. Nouvelles recherches expérimentales sur les ilots de Langerhans. Arch Ital Biol 1909; 51: 123-126.
14. Pratt JH. The internal function of the pancreas. J Am Med Ass 1912; 59: 322-325.
15. Gayet R, Guillaumi M. La régulation de la sécrétion interne pancréatique par un processus humural, démontrée par des transplantations de pancréas. Expériences sur des animaux normaux. CR Soc Biol 1929; 97: 1613-1619.
16. Brooks JR, Gifford GH. Pancreatic homotransplantation. Transplant Bull 1959; 6: 100-106.
17. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967; 61: 827-837.
18. Sutherland DE. Pancreas and island transplantation II. Clinical trials. Diabetologia 1981; 20: 435-450.
19. Calne RY, McMaster PE, Rolles PE, Duffy K. Technical observations in segmental pancreas allografting. Observations on pancreatic blood flow. Transplant Proc 1980; 12: 51.
20. Booster MH, Wijnen RMH, Hooff van JP, Tiebosch ATMG, Peltenburg HG, Berg van den PM, et al. The role of the spleen in pancreas transplantation. Transplantation 1993; 56: 1098-1102.
21. Sollinger HW, Kalayoglu M, Hoffman RM, Belzer FO. Results of segmental and pancreaticosplenic transplantation with pancreaticocystostomy. Transplant Proc 1987; 17: 360-362.
22. Dubernard JM, Traeger J, Neyra P, Touraine JL, Devonec M, Blanc-Brunat N, Ruitcon A. Une nouvelle méthode de préparation du greffon pancréatique en vue de la transplantation: données expérimentales et applications cliniques au cours de 9 transplantations chez 8 sujets diabetiques. Chirurgie 1978; 104: 242-258.
23. Dubernard JM, Traeger J, Neyra, Touraine JL, Blanc, Devonec M. Long-term effect of neoprene injection in the canine pancreatic duct. Transplant Proc 1979; 11: 1498-1499.
24. Groth CG, Lundgren G, Gunnarsson R, Arner P, Berg B, Ostman J. Segmental pancreatic transplantations with duct ligation or drainage to a jejunal Roux-en-Y loop in nonuremic diabetic patients. Diabetes 1980; 29 (suppl 1): 3-9.
25. Dickerman RM, Twiest MW, Crudup JW, Turcotte JG. Transplantation of the pancreas into a retroperitoneal jejunal loop. Amer J Surg 1976; 129: 48-54.
26. Largiadèr F, Lyons GW, Hidalgo F, Dieteman RH, Lillehei RC. Orthotopic allotransplantation of the pancreas. Amer J Surg 1967; 113: 70-76.
27. Groth CG, Tyden G, Ostman J. Fifteen years experience with pancreas transplantation with pancreaticoenterostomy. Diabetes 1989; 38 (suppl 1): 13-15.
28. Cook F, Sollinger HW, Warner T, Kamps D, Belzer FO. Pancreaticocystostomy: an alternative method for exocrine drainage of segmental pancreatic allografts. Transplantation 1983; 35: 634-636.
29. Sollinger HW, Stratta RJ, Kalayoglu M, Pirsch JD, Belzer FO. Pancreas transplantation with pancreaticoocystostomy and quadruple immunosuppression. Surgery 1987; 102: 674-679.
30. Kuo P, Johnson L, Schweitzer E, Delatorre A, Barlett S. Simultaneous pancreas-kidney transplantation (SPK); a comparison of enteric and bladder drainage of exocrine pancreatic secretion. Transplant Proc 1997; in press.
31. Nymann T, Elmer D, Shokouh-Amirim H, Gaber AO. Improved outcome on patients with portalenteric pancreas transplantation. Transplant Proc 1997; 29: 637-638.
32. Davidson I, Lu C, Stephan R. Intestinal drainage of the exocrine pancreatic allograft revisited, a better choice? Transplant Proc 1997; 29: 639.
33. Corry RJ, Egidi MF, Shapiro R, Jordan M, Dodson SF, Scantlebury V, et al. Pancreas transplantation with enteric drainage under tacrolimus induction therapy. Transplant Proc 1997; 29: 642.
34. Wahlberg JA, Love R, Landegaard L, Southard JH, Belzer FO. 72-hour preservation of the canine pancreas. Transplantation 1987; 43: 5-8.
35. Prieto M, Sutherland DER, Fernandez-Cruz L, Heil J, Najarian JS. Experimental and clinical experience with urine amylase monitoring for early diagnosis of rejection in pancreas transplantation. Transplantation 1987; 43: 73-79.
36. Schulak JA, Drevyanko TF. Experimental pancreas allograft rejection: correlation between histologic and functional rejection and the efficacy of antirejection therapy. Surgery 1985; 98: 330.
37. Tyden G, Lundgren G, Gunnarsson R, Wilzcek H, Klintmalm G, et al. Laboratory findings during rejection of segmental pancreatic allografts. Transplant Proc 1984; 16: 715.
38. Nyberg G, Olavsson M, Norden G, Mjornstedt L, Blohme I, Hedman L. Pancreas specific protein monitoring in pancreas transplantation. Transplant Proc 1991; 23: 1604-1605.
39. Marks WH, Borgstrom A, Sollinger H, Marks C. Serum immunoreactive anodal trypsynogen and urinary amylase as biochemical markers for rejection of clinical wholeorgan pancreas allografts having exocrine drainage into the urinary bladder. Transplantation 1990; 49: 112-115.
40. Sollinger HW, Stratta RJ, D'Allesandro AM. Experience with simultaneous pancreas-kidney transplantation. Ann Surg 1988; 208: 475-483.
41. Sutherland DER, Moudry KC, Dunn DL, Goetz FC, Najarian JS. Results of pancreas transplant registry. Diabetes 1989; 38 (suppl 1): 10-12.
42. Sutherland DER, Kendall DM, Moudry KC, Navarro X, Kennedy WR, Ramsay RC, et al. Pancreas transplantation in nonuremic, type I diabetic recipients. Surgery 1988; 104: 453-464.
43. Sutherland DER, Moudry KC. Pancreas transplant registry report 1986. Clin Transplant 1987; 1: 3-17.
44. American Diabetes Association. Pancreas transplantation for patients with diabetes mellitus. Diabetes Care 1992; 15: 1669-1673.
45. Yamashita T, Maeda Y, Ishikawa T, Ohira M, Nakagawa H, Nagai Y, et al. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK506. Transplant Proc 1991; 23: 3219-3220.
46. Ohtsuka S, Hayashi S, Sato E, Tanaka Y, Hachisuka T, Haba T, et al. The effect of short-term FK506 therapy on pancreas transplantation in rats. Transplant Proc 1991; 23: 3217-3218.
47. Morimoto T, Yamada F, Kobayashi T, Miyaishi S, Tokumaru T, Kamiya I, et al. Pancreaticoduodenal allotransplantation with FK506 in the dog. Transplant Proc 1990; 22: 717-719.
48. Ohara K, Billington R, James RW, Dean GA, Nishiyama M, Noguchi H. Toxicologic evaluation of FK506. Transplant Proc 1990; 22: 83-86.
49. Ochiai T, Nagata M, Nakajima K, Sakamoto K, Asno T, Isono K. Prolongation of canine renal allograft survival by treatment of FK506. Transplant Proc 1987; 19: 53-56.
50. Todo S, Demetris AJ, Ueda Y, Imventarza O, Okuda K, Casavilla A, et al. Canine kidney transplantation with FK506 alone or in combination with cyclosporine and steroids. Transplant Proc 1987; 14: 57-61.
51. Collier DStJ, Thiru S, Calne R. Kidney transplantation in the dog receiving FK506. Transplant Proc 1987; 19: 62.
52. Sato K, Yamagishi K, Nakayama Y, Yokota K, Uchida H, Masaki Y, et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. Transplant Proc 1989; 21: 1074-1075.
53. Imai K, Sato K, Takishima I, Nakayama Y, Osakabe T, Yokota K, et al. Pancreaticoduodenal allotransplantation with the use of FK506, Cyclosporine, and triple-regimen immunosuppression. Transplant Proc 1990; 22: 1655-1657.
54. Imventarza O, Todo S, Eiras G, Ueda Y, Furukawa H, Wu YM, et al. Renal transplantation in balloons under FK506. Transplant Proc 1990; 22: 64-65.
55. Collier DStJ, Calne R, Thiru S, Friend PJ, Lim S, White DJG, et al. FK506 in experimental renal allografts in clogs and primates. Transplant Proc 1988; 20: 226-228.
56. Todo S, Demetris A, Ueda Y, Imventarza O, Cadoff E, Zeevi A, et al. Renal transplantation in baboons under FK506. Surgery 1989; 106: 444-451.
57. Monden M, Gotoh M, Kanai T, Valdivia LA, Umeshita K, Endoh W, et al. A potent immunosuppressive effect of FK506 in orthotopic liver transplantation in primates. Transplant Proc 1990; 22: 66-71.
58. Hildebrandt A, Meiser B, Human P, Reichenspurner H, Rose A, Odell J, et al. FK506: short- and long-term treatment after cardiac transplantation in nonhuman primates. Transplant Proc 1991; 23: 509-510.
59. Flavin T, Ivens K, Wang I, Gutierrez J, Hoyt EG, Billingham M, et al. Initial experience with FK506 as an immunosuppressant for non-human primate recipients of cardiac allografts. Transplant Proc 1991; 23: 531-532.
60. Thiru S, Collier DStJ, Calne R. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK506. Transplant Proc 1987; 19: 98-99.
61. Wijnen RMH, Ericzon BG, Tiebosch A, Buurman WA, Groth CG, Kootstra G. Toxicology of FK506 in the cynomolgus monkey; a clinical, biochemical, and histological study. Transplant Int 1992; 53 (suppl 5): S454-S458.
62. Ericzon BG, Wijnen RMH, Kubota K, Kootstra G, Groth CG. FK-506 induced impairment of glucose metabolism in the primate: studies in pancreatic transplant recipients and non-transplanted animals. Transplantation 1992; 54: 615-620.
63. Ericzon BG, Wijnen RMH, Tiebosch A, Kubota K, Kootstra G, Groth CG. The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. Transplantation 1992; 53: 1184-1189.
64. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese diabetic strain of mice. Exp Anim 1980; 29: 1-13.
65. Laupacis A, Stiller CR, Cardell C, Keown P, Dupre I, Wallace AC. Cydosporin prevents diabetes in BB Wistar rats. Lancet 1983; 1: 10-12.
66. Brayman KL, Armstrong BA, Shaw LM, Rosaro TG, Tomaszewski JE, Barker CF, et al. Prevention of diabetes in BB rats by intermittent administration of cyclosporine. Surgery 1987; 102: 235-241.
67. Stiller CR, Dupre J, Gent M, Jenner MR, Keown PA, Laupads A, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223: 1362-1367.
68. Assan R, Feutren G, Debray-Sachs M, Quiniou-Debrie MC, Laborie C, Thomas G, et al. Metabolic and immunological effects of cyclosporin in recently diagnosed type I diabetes mellitus. Lancet 1985; 1: 67-71.
69. Stiller CR, Dupre J. Immune interventional studies in type I diabetes: summary of the London (Canada) and Canadian-European experience. In: Eisenbarth GS, ed. Immunotherapy of Diabetes and Selected Autoimmune Diseases. Boca Raton, FL: CRC Press, 1989: 73-84.
70. Miyagawa J, Yamamoto K, Hanafusa T, Itoh N, Nakagawa C, Otsuka A, et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. Diabetologia 1990; 33: 503-505.
71. Murase N, Lieberman I, Nalesnik MA, Mintz DH, Todo S, Drash AL, Starzl TE. Effect of FK506 on spontaneous diabetes in BB rats. Diabetes 1990; 39: 1584-1586.
72. Nobuhiro K, Koichi M, Tsukasa T, Takashi K. Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. Transplantation 1993; 55: 936-940.
73. Kurasawa K, Koike T, Matsumura R, Takabayashi K, Tomoika H, Ito I, et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. Clin Immunology and Immunopath 1990; 57: 274-279.
74. Yale JF, Grose M, Seemayer TA, Marliss EB. Immunological and metabolic concomitants of cyclosporin prevention of diabetes in BB rats. Diabetes 1987; 36: 749-757.
75. Murase N, Lieberman I, Nalesnik M, Mintz D, Todo S, Drash AL, et al. Prevention of spontaneous diabetes in BB rats with FK506. Lancet 1990; 336: 373-374.
76. Leonard DK, Landry AS, Sollinger HW, Hullett DA. Toxicity of FK-506 in human fetal pancreas. Diabetes 1989; 38 (suppl 1): 172-175.
77. Tze WJ, Tai J, Cheung S. In vitro effects of FK-506 on human and rat islets. Transplantation 1990; 49: 1172-1174.
78. Ricordi C, Zeng Y, Alejandro R, Tzakis A, Venkataramanan R, Fung J, et al. In vivo effect of FK506 on human pancreatic islets. Transplantation 1991; 52: 519-522.
79. Ishizuka J, Gugliuzza KK, Wassmuth Z, Hsieh J, Sato K, Tsuchiya T, et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation 1993; 56: 1486-1490.
80. Carroll PB, Boscherd AC, Li MY, Tzakis AG, Starzl TE, Atwater I. Effect of the immunosuppressant FK506 on glucose induced insulin secretion from adult rat islets of Langerhans. Transplantation 1991; 51: 275-277.
81. Strasser S, Alejandro R, Ricordi C, Todo S, Mintz DH. The effect of FK506 on canine pancreatic islet cell function in beagle dogs. Transplant Proc 1991; 23: 756.
82. Ericzon BG, Wijnen RMH, Kubota K, Kootstra G, Groth CG. Effect of FK506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and non-transplanted animals. Transplant Proc 1991; 23: 756.
83. Calne R, Collier DS, Thiru S. Observations about FK506 in primates. Transplant Proc 1987; 19 (suppl 6): 63.
84. Tamura K, Fujimura T, Tsutsumi T, Nakamura K, Ogawa T, Atamura C, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic B-cell. Transplantation 1995; 59: 1606-1611.
85. Hirano Y, Hisatomi A, Ohara K, Naguchi H. The effect of FK506 and cyclosporin on the exocrine function of the rat pancreas. Transplantation 1992; 54: 883-887.
86. Ohara K, Billington R, James RW, Dean GA, Nishiyama M, Noguchi H. Toxicologic evaluation of FK506. Transplant Proc 1990; 22 (suppl 1): 83-86.
87. Herold KC, Nagamatsu S, Buse JB, Kulsakdinun P, Steiner DF. Inhibition of glucose-stimulated insulin release from BTC3 cells and rodent islets by an analog of FK506. Transplantation 1993; 55: 186-192.
88. European FK506 Multicentre Liver Study Group. Randomized trial comparing tracolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344(i): 423-428.
89. The U.S. Multicenter FK506 Liver Study Group. A comparison of tracolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-1115.
90. Hooff van J, Buchholz B, Eigler FW, Ericzon BG, Grabensee B, Johnson RWG, et al. The European Tacrolimus Multicentre Renal Study Group. The European multicentre prospective randomised trial comparing tacrolimus and cyclosporin in the prevention of renal allograft rejection. Transplant Proc 1997; in press.
91. Miller J. The FK506 U.S. Kidney Transplant Multicenter Study Group. FK506 in kidney transplantation: results of the U.S. randomized comparative, phase III study. Transplant Proc 1997; 29: 304-305.
92. Gruessner A, Sutherland DER. Pancreas transplant results in the United Network of Organ Sharing (UNOS) USA Registry compared with non-USA data in the International Registry. Clin Transplant 1994: 47-68.
93. Shaffer D, Simpson MA, Conway P, Madras PN, Monaco AP. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). Transplantation 1995; 59: 1063-1066.
94. Hariharan S, Peddi VR, Munda R, Demmy AM, Schroeder TJ, Alexander JW, et al. Long-term renal and pancreas function with tacrolimus rescue therapy following pancreas transplantation. Transplant Proc 1997; 29: 652-653.
95. Hariharan S, Munda R, Demmy TJ, Schroeder TJ, Alexander JW, First MR. Conversion from cyclosporine to tacrolimus after pancreas transplantation. Transplant Proc 1995; 27: 2981-2982.
96. Teraoka S, Babazono T, Koike T, Abe M, Kimikawa M, Shinkai M, et al. Effect of rescue therapy using FK506 on relapsing rejection after combined pancreas and kidney transplantation. Transplant Proc 1995; 27: 1335-1339.
97. Sutherland DER, Gruessner RWG, Gruessner AC. Solitary pancreas transplants: improving results and factors that influence outcome. Transplant Proc 1997; 29: 664-665.
98. El-Ghoroury M, Hariharan S, Peddi VR, Munda R, Schroeder TJ, Demmy A, et al. Efficacy and safety of tacrolimus (FK) vs cyclosporine (CyA) in kidney and pancreas transplant. Transplant Proc 1997; 29: 649-651.
99. Swanson G, Rubin M, Colquhoun S, Basadonna G, Asshinnik A, Perez R. FK506-based immunosuppression in clinical pancreas transplantation. Transplant Proc 1995; 27: 3031.
100. Stratta RJ, Taylor RJ, Castaldo P, Sindhi R, Sudan D, Frisbie K, et al. Preliminary experience with FK506 in pancreas transplant recipients. Transplant Proc 1995; 27: 3024.
101. Ketel BL, Turton-Weeks S, Reed K, Barone GW. Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation. Transplant Proc 1996; 28: 899.
102. Stratta RJ, Taylor RJ, Castaldo P, Sindhi R, Sudan D, Frisbie K, et al. FK506 induction and rescue therapy in pancreas transplant recipients. Transplant Proc 1996; 28: 991-992.
103. Greussner RWG, Burke GW, Stratta R, Sollinger H, Benedetti E, Marsh C, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996; 61: 261-273.
104. Henley SE, Larsen JL, Miller SA. Fasting lipids temporarily worsen after solitary pancreas transplantation. Abstract presented at International Islet and Pancreas Transplantation Meeting, June 1995.
105. Jindal RM, Popescu I, Emre S, Schwartz ME, Boccagni P, Meneses P, et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine vs FK506. Transplantation 1994; 57: 1395-1398.
106. Henley SE, Earsen JE, Mack-Shipman E, Miller SA, Gushing KA, Stratta RJ. Eipids following pancreas transplantation in recipients receiving FK506. Transplant Proc 1995; 27: 2997.
107. Burke GW, Alejandro R, Roth D, Colona J, Contreras N, Ciancio G, et al. Use of FK506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. Transplant Proc 1995; 27: 3119-3120.
108. The Scandinavian Simvastatin Survival Study (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-1389.
109. Laakso M, Lehto S, Pentilla I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin dependent diabetes. Circulation 1993; 88: 1421-1430.
110. Engfeldt P, Tyden G, Gunarson R, Ostman J, Groth CG. Impaired glucose tolerance with cyclosporin. Transplant Proc 1986; 18: 65.
111. Nakai I, Omori Y, Aikawa I, Yasumura T, Suzuki S, Yoshimura N, et al. Effect of cyclosporin on glucose metabolism in kidney transplant recipients. Transplant Proc 1988; 20: 969-978.
112. Sumrani NB, Delaney V, Ding Z, Davis R, Daskalakis P, Friedman EA, et al. Diabetes mellitus after renal transplantation in the cyclosporine era - an analysis of risk factors. Transplantation 1991; 51: 343-347.
113. Boudreaux JP, McHugh E, Canafax DM, Ascher N, Sutherland DER, Payne W, et al. The impact of cyclosporine and combination immunosuppression on the incidence of post-transplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376-381.
114. Yoshimura N, Nakai I, Ohmori Y, Aikawa I, Fukuda M, Yasumura T, et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis 1988; 1: 11-17.
115. Roth D, Milgrom M, Esquenazi V, Fuller E, Burke G, Miller J. Posttransplant hyperglycaemia. Increased incidence in cyclosporin-treated renal allograft recipients. Transplantation 1989; 47: 278-281.
116. Alejandro R, Feldman EC, Bloom AD, Kenyon NS. Effects of cyclosporin on insulin and c-peptide secretion in healthy beagles. Diabetes 1989; 38: 696-703.
117. Yale JB, Chamelian M, Courchosno S, Vigeant C. Peripheral insulin resistance and decreased insulin secretion after cyclosporin A treatment. Transplant Proc 1988; 20: 985-988.
118. Gunnarsson R, Klintmalm G, Lundgren G, Wilczek H, Östman J, Groth CG. Deterioration in glucose metabolism in pancreatic transplant recipients given cyclosporine. Lancet 1983; 2: 71-72.
119. Ochiai T, Ishibashi M, Fukao K, Takuhashi K, Endo T, Yokoyama I, et al. Japanese multicenter studies of FK506 in renal transplantation. Transplant Proc 1995; 27: 50-53.
120. Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, et al. New onset of diabetes in FK506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23: 3169-3170.
121. Krentz AJ, Dousset B, Mayer D, McMaster P, Buckels J, Cramb R, et al. Metabolic effects of cyclosporine A and FK506 in liver transplant recipients. Diabetes 1993; 42: 1753-1759.
122. Jindahl RM, Popescu I, Schwartz ME, Emre S, Boccagni P, Miller CM. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. Transplantation 1994; 58: 370-372.
123. Senninger N, Golling M, Datsis K, Sido B, Herfarth C, Otto G. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK506. Transplant Proc 1995; 27: 1127-1128.
124. Mieles L, Gordon RD, Mintz D, Toussaint RM, Imventarza O, Starzl TE. Glycemia and insulin need following FK506 rescue therapy in liver transplant recipients. Transplant Proc 1995; 23: 949-953.
125. Steinmuller TM, Graf KJ, Schleicher, Leder K, Bechstein WO, Mueller AR, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism - a randomized trial. Transplantation 1994; 58: 669-674.
126. Ericzon BG, Groth CG, Bismuth A, Calne R, McMaster P, Neuhaus P, et al. Glucose metabolism in liver transplant recipients treated with FK506 or cyclosporin in the European multicentre study. Transpl Int 1994; 7 (suppl 1): S11-S14.
127. Stratta RJ, First MR, Egidi F, Corry RJ, Johnson CP, Marsh CL, et al. Simultaneous use of FK506 and mycophenolate mofetil in pancreas and kidney transplant recipients: a multicenter report. Transplant Proc 1997; 29: 654-655.